| 今开：1.26 | 昨收：1.26 |
| 最高：1.33 | 最低：1.2495 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：9.4069518E7 |
Aclaris Therapeutics(ACRS)04-25 19:05
$Aclaris Therapeutics(ACRS)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001558370-24-005679 Act: 34 Size: 381 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)05-08 04:15
$Aclaris Therapeutics(ACRS)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-24-057991 Act: 33 Size: 80 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-05 04:35
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015366 Size: 13 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-05 04:35
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015365 Size: 13 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-05 04:35
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-015364 Size: 13 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-11 04:25
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016192 Size: 8 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)04-25 19:05
$Aclaris Therapeutics(ACRS)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-24-005677 Act: 34 Size: 3 MB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-11 04:25
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016196 Size: 8 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-11 04:25
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016193 Size: 8 KB 网页链接查看全文
Aclaris Therapeutics(ACRS)06-11 04:25
$Aclaris Therapeutics(ACRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-016195 Size: 7 KB 网页链接查看全文
丰硕创投04-19 16:22
$Aclaris Therapeutics(ACRS)$ 2024年1月10日，Aclaris公司宣布JAK1/3抑制剂ATI-1777，用于治疗中重度AD的2b期试验结果，结果不理想，该药物为喷雾制剂。
主要疗效终点第4周EASI评分，2%QD剂量组不具备统计学差异。
FDA监管终点，第4周IGA-TS评分，2%BID和2%QD剂量组均不具有统计学差异查看全文
chuminhua2023-11-14 11:26
11/13，周一，Aclaris Therapeutics $Aclaris Therapeutics(ACRS)$ 宣布计划取消 zunsemetinib 的开发，该公司正在评估口服 MK2 抑制剂zunsemetinib对中重度类风湿性关节炎 (RA) 患者的疗效，该公司股价周一下跌超过 85%。 此举还延伸到 Aclaris 正在进行的 zunsemetinib 治疗银屑病关节炎的 IIa ...查看全文
牛唐2023-08-07 21:42
医药板块速评（2022.08.04）
1、哪些LOW float医药股值得关注？
2、$Ascendis制药(ASND)$后续走势有何看点？
3、 $强生(JNJ)$ 、$微软(MSFT)$ 、$Aclaris Therapeutics(ACRS)、$梯瓦制药(TEVA)等期权大量成交，后续走势如何看？查看全文
北美咨询网2023-03-08 09:01
周一的美国生物医药股市场涨跌互见。
BridgeBio Pharma展示了治疗限制生长的疾病的积极试验结果。
在试验未能达到主要和次要终点后，Aclaris Therapeutics的股价急剧下跌。
谁是赢家，谁是输家？
周一股市开局良好，不同类型股票之间存在相当大的差异。小型股指数大幅下跌，但道琼...查看全文
产业链观察2023-03-06 20:19
#药闻简讯# $Aclaris Therapeutics(ACRS)$ 宣布口服Zunsemetinib（ATI-450）治疗中度至重度化脓性皮炎的12周2a期研究的初步初步数据。研究未达到化脓性皮炎的主要或次要疗效终点。#临床研究失败# $InflaRx(IFRX)$查看全文
美股滚雪球2022-11-30 10:34
$Aclaris Therapeutics(ACRS)$ 和祐儿医药宣布两家公司已经签署了许可协议。
根据许可协议，Aclaris已授权祐儿医药在大中华区独家开发、生产和商业化ATI-1777。Aclaris将保留在世界其他地区开发、制造和商业化ATI-1777的权利。
根据协议条款，Aclaris将获得500万美元的预付款。此外，如果...查看全文
$Aclaris Therapeutics, Inc.(ACRS)$ 8-K - Current report Filed: 2017-08-09 AccNo: 0001558370-17-006416 Size: 63 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 7....
$Aclaris Therapeutics, Inc.(ACRS)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2017-08-09 AccNo: 0001047469-17-005132 Size: 448 KB 网页链接
$Aclaris Therapeutics, Inc.(ACRS)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-08-08 AccNo: 0001558370-17-006211 Size: 5 MB 网页链接
$Aclaris Therapeutics, Inc.(ACRS)$ 8-K - Current report Filed: 2017-08-08 AccNo: 0001558370-17-006206 Size: 206 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Aclaris Therapeutics, Inc.(ACRS)$ 8-K - Current report Filed: 2017-08-08 AccNo: 0001558370-17-006203 Size: 2 MBItem 1.01: Entry into a Material Definitive AgreementItem 2.01: Completion of Acquisition or Disposition of AssetsItem 3.02: Unregistered Sales of Equity Securities...
$Aclaris Therapeutics, Inc.(ACRS)$ 8-K - Current report Filed: 2017-08-08 AccNo: 0001558370-17-006206 Size: 206 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Aclaris Therapeutics, Inc.(ACRS)$ 8-K - Current report Filed: 2017-08-08 AccNo: 0001558370-17-006203 Size: 2 MBItem 1.01: Entry into a Material Definitive AgreementItem 2.01: Completion of Acquisition or Disposition of AssetsItem 3.02: Unregistered Sales of Equity Securities...
$Aclaris Therapeutics, Inc.(ACRS)$ 美东时间 2017-08-08 盘前 披露财报，预期EPS -0.68 网页链接
$Aclaris Therapeutics, Inc.(ACRS)$ 8-K - Current report: n Filed: 2017-08-01 AccNo: 0001558370-17-005594 Size: 494 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersIte...
$Aclaris Therapeutics(ACRS)$ 8-K - Current report Filed: 2017-06-16 AccNo: 0001104659-17-039962 Size: 32 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接